Patent classifications
A61K31/501
TRICYCLIC SPIRO COMPOUND
A medicinal agent for the prevention and/or treatment of diseases caused by EP.sub.4 receptor activation. A compound having antagonistic activity against the EP.sub.4 receptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EP.sub.4 receptor for the prevention and/or treatment of diseases caused by EP.sub.4 receptor activation.
##STR00001##
PIPERIDINE AND AZEPINE DERIVATIVES AS PROKINETICIN RECEPTOR MODULATORS
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof (Formula (I)) in which m, X, R.sup.1, R.sup.2, R.sup.3 and R.sup.5 are as defined in the specification, processes for their preparation, pharmaceutical compositions N containing them and their use in therapy.
##STR00001##
PIPERIDINE AND AZEPINE DERIVATIVES AS PROKINETICIN RECEPTOR MODULATORS
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof (Formula (I)) in which m, X, R.sup.1, R.sup.2, R.sup.3 and R.sup.5 are as defined in the specification, processes for their preparation, pharmaceutical compositions N containing them and their use in therapy.
##STR00001##
QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF
This invention provides compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein T, J, R, R.sup.4, R.sup.q, o, R.sup.A, W and R.sup.B and subsets thereof are as described in the specification. The compounds are inhibitors of NAMPT and are thus useful for treating cancer, inflammatory conditions, and/or T-cell mediated autoimmune disease.
##STR00001##
QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF
This invention provides compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein T, J, R, R.sup.4, R.sup.q, o, R.sup.A, W and R.sup.B and subsets thereof are as described in the specification. The compounds are inhibitors of NAMPT and are thus useful for treating cancer, inflammatory conditions, and/or T-cell mediated autoimmune disease.
##STR00001##
IRAK degraders and uses thereof
The present invention provides compounds, compositions thereof, and methods of using the same.
IRAK degraders and uses thereof
The present invention provides compounds, compositions thereof, and methods of using the same.
COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF
The present invention relates to the technical field of medicines. Specifically disclosed is a compound as represented by formula I′, or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, symbols therein being as defined in the claims. The compound of the present invention may be used as a drug for regulating RET kinase activity or treating RET-related diseases, and has good pharmacokinetic properties.
##STR00001##
METHODS OF TREATING CARTILAGE DISORDERS THROUGH INHIBITION OF CLK AND DYRK
Provided herein are methods of treating cartilage disorders in a subject using a dual CLK/DYRK inhibitor, or a pharmaceutically acceptable salt of solvate thereof, or a combination of a CLK inhibitor, or a pharmaceutically acceptable salt of solvate thereof, and DYRK inhibitor or, pharmaceutically acceptable salt or solvate thereof.
METHODS OF TREATING CARTILAGE DISORDERS THROUGH INHIBITION OF CLK AND DYRK
Provided herein are methods of treating cartilage disorders in a subject using a dual CLK/DYRK inhibitor, or a pharmaceutically acceptable salt of solvate thereof, or a combination of a CLK inhibitor, or a pharmaceutically acceptable salt of solvate thereof, and DYRK inhibitor or, pharmaceutically acceptable salt or solvate thereof.